Insight Molecular Diagnostics is no longer an oncology lab leftover trading on a leftover name. The former Oncocyte is now a single-product wager on whether the first kitted donor-derived cell-free DNA assay for kidney-transplant rejection clears Food and Drug Administration marketing authorization before cash runs thin. Late July closed the current phase of substantive review after a late-March submission, and the agency asked for more information that management calls routine. The equity already prices that authorization as more likely than not. The income statement still describes a pre-kit company.
The commercial setup improved even while the kit remains unauthorized. Medicare's MolDX program issued a local coverage decision in mid-July that lifts covered surveillance frequency in the later post-transplant years and confirms payment for treatment-response monitoring. Peer-reviewed head-to-head work showed near-complete agreement with a leading next-generation sequencing assay and a lower limit of quantification. None of that produces kit revenue until authorization lands. Combined cash sat at $18.7 million at mid-year. Second-quarter outgoing free cash flow was about $10 million.
The second-quarter print is the income statement of a company that has already abandoned the old service model. Laboratory services at the Nashville CLIA site still account for almost all billed work. Research-use kit sales remain a rounding error until authorization converts the catalog from investigational to commercial. Gross margin on that thin base stayed high, which shows the remaining work is still profitable even as the company starves the old line on purpose. The GAAP loss widened because a non-cash mark on Chronix-related contingent consideration flipped from a first-quarter gain to a second-quarter charge. Adjusted loss narrowed sequentially once that mark and stock-based pay are stripped out.
The market values the equity at about $132 million after the mid-September close. The last print sat near $4.02. That is not a multiple on current sales. It is an option on a kitted franchise in a transplant-monitoring category that send-out specialists already occupy. The debate is whether authorization, a short Bio-Rad commercial-rights window, and hospital-lab adoption arrive while cash still covers an elevated quarterly burn. If authorization slips or launch pricing stays discounted to win the first centers, another equity raise sits on the path before kit revenue can fund the platform. That is the whole tape. Everything else is color.